S. Kronenberg

Nivolumab plus ipilimumab in advanced melanoma.

C. Horak, J. Wolchok, M. Sznol, 2013, The New England journal of medicine.

Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS-936558, ONO-4538) and ipilimumab (IPI) concurrent therapy in advanced melanoma (MEL).

J. Wolchok, M. Atkins, J. Kirkwood, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

1085OSURVIVAL, RESPONSE DURATION, AND ACTIVITY BY BRAF MUTATION (MT) STATUS IN A PHASE 1 TRIAL OF NIVOLUMAB (ANTI-PD-1, BMS-936558, ONO-4538) AND IPILIMUMAB (IPI) CONCURRENT THERAPY IN ADVANCED MELANOMA (MEL).

J. Wolchok, M. Atkins, J. Kirkwood, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Melanoma and immunotherapy bridge 2015

Andrew J. Park, A. Hauschild, J. Malvehy, 2016, Journal of Translational Medicine.

A phase 1 study of PF-05082566 (anti-4-1BB) in patients with advanced cancer.

Craig B. Davis, H. Kohrt, R. Houot, 2014 .

Melanoma and immunotherapy bridge 2015

Andrew J. Park, David C. Smith, A. Hauschild, 2016, Journal of Translational Medicine.

Safety and clinical activity of nivolumab (anti-PD-1, BMS-936558, ONO-4538) in combination with ipilimumab in patients (pts) with advanced melanoma (MEL).

C. Horak, J. Wolchok, M. Sznol, 2013 .

Concurrent Radiation Therapy (RT), Ipilimumab (Ipi) and/or Nivolumab (Nivo) on a Phase 1 Clinical Trial

Y. Yamada, J. Wolchok, T. Chan, 2015 .